The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic NeoplasmsJoseph D. Khoury, Andreas Hochhaus|Leukemia|2022Cited by 3.8k
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trialAndreas Hochhaus, Hagop M. Kantarjian|Leukemia|2016Cited by 849
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trialRalf‐Dieter Hofheinz, Andreas Hochhaus, Frederik Wenz et al.|The Lancet Oncology|2012Cited by 505
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor FailureTimothy P. Hughes, Dong‐Wook Kim, Michael J. Mauro et al.|New England Journal of Medicine|2019Cited by 464
Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group [see comments]Rüdiger Hehlmann, B Heinze, H. Heimpel et al.|Blood|1994Cited by 458